Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06392724 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06392724 · ClinicalTrials.gov record · last posted 2025-07-29

A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy.

Study acronym: GEN6050XIIT
StatusActive, Not Recruiting
PhaseEarly Phase 1
Started2024-07-05
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 29, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
The study will evaluate the safety and tolerability of GEN6050X gene therapy in Duchenne muscular dystrophy (DMD) patients amenable to exon 50 skipping.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2024-04-29; most recent amendment 2025-07-24. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-07-24
Status change Recruiting→Active, Not Recruitingv7
2024-07-04
Status change Not Yet Recruiting→Recruitingv6
Trial Details
NCT Number NCT06392724
Lead Sponsor Peking Union Medical College Hospital
Conditions Duchenne Muscular Dystrophy (DMD)
Enrollment 3 participants
Start Date 2024-07-05
Primary Completion 2025-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-29